好、坏、丑：免疫检查点治疗后癌症患者的超进展。
The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy.
机构信息
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Genome Med. 2019 Jul 24;11(1):43. doi: 10.1186/s13073-019-0661-7.
Abstract
Immune checkpoint blockade therapy can elicit robust and durable responses in a variety of cancer types. While many patients do not respond, recent reports highlight a distinct group of patients whose tumors undergo rapid growth, leading to progressive disease and poor outcome. In this perspective, we synthesize and summarize some important issues surrounding hyperprogression, defining characteristics, prognostic implications, and controversies.
摘要
免疫检查点阻断疗法可以在多种癌症类型中引发强烈和持久的反应。虽然许多患者没有反应，但最近的报告强调了一个独特的患者群体，他们的肿瘤会迅速生长，导致疾病进展和预后不良。在这个观点中，我们综合和总结了一些围绕超进展的重要问题，包括定义特征、预后意义和争议。
相似文献
1
The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy.好、坏、丑：免疫检查点治疗后癌症患者的超进展。
Genome Med. 2019 Jul 24;11(1):43. doi: 10.1186/s13073-019-0661-7.
2
Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.基于肿瘤微环境的检查点阻断免疫疗法：机遇与挑战。
Cancer Med. 2018 Sep;7(9):4517-4529. doi: 10.1002/cam4.1722. Epub 2018 Aug 7.
3
Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.免疫检查点抑制剂时代的肿瘤浸润淋巴细胞
Curr Hematol Malig Rep. 2019 Aug;14(4):286-291. doi: 10.1007/s11899-019-00523-x.
4
Immune checkpoint inhibitors: The linchpins of modern immunotherapy.免疫检查点抑制剂：现代免疫疗法的关键。
Immunol Rev. 2019 Jul;290(1):6-23. doi: 10.1111/imr.12766.
5
Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.胶质母细胞瘤中免疫检查点阻断的临床试验研究
Curr Treat Options Oncol. 2017 Aug;18(8):51. doi: 10.1007/s11864-017-0492-y.
6
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.原发性和获得性耐药免疫检查点抑制剂治疗转移性黑色素瘤。
Clin Cancer Res. 2018 Mar 15;24(6):1260-1270. doi: 10.1158/1078-0432.CCR-17-2267. Epub 2017 Nov 10.
7
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.免疫检查点抑制剂治疗转移性黑色素瘤：癌症免疫治疗的范例。
Semin Cancer Biol. 2019 Dec;59:290-297. doi: 10.1016/j.semcancer.2019.08.001. Epub 2019 Aug 17.
8
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition.免疫检查点抑制背景下的甲状腺癌免疫全景。
Int J Mol Sci. 2019 Aug 13;20(16):3934. doi: 10.3390/ijms20163934.
9
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.血管生成素-2 作为免疫检查点治疗的生物标志物和靶点。
Cancer Immunol Res. 2017 Jan;5(1):17-28. doi: 10.1158/2326-6066.CIR-16-0206. Epub 2016 Dec 21.
10
Immune Checkpoint Inhibitors in Organ Transplant Patients.器官移植患者中的免疫检查点抑制剂
J Immunother. 2017 Sep;40(7):277-281. doi: 10.1097/CJI.0000000000000180.
引用本文的文献
1
Case Report: Exploring delayed hyperprogressive disease: a case study of post-immunotherapy in lung cancer.病例报告：探索延迟性高进展性疾病：肺癌免疫治疗后的病例研究
Front Immunol. 2025 Apr 17;16:1552547. doi: 10.3389/fimmu.2025.1552547. eCollection 2025.
2
Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors.免疫检查点抑制剂治疗开始后脑转移瘤的超进展
J Neurooncol. 2025 May;172(3):667-673. doi: 10.1007/s11060-025-04955-9. Epub 2025 Feb 7.
3
TMEM173 is a biomarker of predicting prognosis, immune responses and therapeutic effect in human lung adenocarcinoma.跨膜蛋白173（TMEM173）是预测人类肺腺癌预后、免疫反应和治疗效果的生物标志物。
Discov Oncol. 2024 Oct 30;15(1):604. doi: 10.1007/s12672-024-01482-3.
4
PD-L1: From cancer immunotherapy to therapeutic implications in multiple disorders.程序性死亡受体配体1：从癌症免疫疗法到在多种疾病中的治疗意义
Mol Ther. 2024 Dec 4;32(12):4235-4255. doi: 10.1016/j.ymthe.2024.09.026. Epub 2024 Sep 28.
5
Non‑small cell lung cancer carrying PBRM1 mutation suggests an immunologically cold phenotype leading to immunotherapy failure even with high TMB.携带PBRM1突变的非小细胞肺癌表现出免疫冷表型，即使肿瘤突变负荷高也会导致免疫治疗失败。
Sci Rep. 2022 Dec 1;12(1):20734. doi: 10.1038/s41598-022-25050-3.
6
Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review.免疫治疗下的超进展：一种新的免疫治疗反应形式？——一篇叙述性文献综述
Transl Lung Cancer Res. 2021 Jul;10(7):3276-3291. doi: 10.21037/tlcr-21-575.
7
TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model.TGF-β 抑制可以克服癌症对 PD-1 阻断的原发性耐药：一个数学模型。
PLoS One. 2021 Jun 1;16(6):e0252620. doi: 10.1371/journal.pone.0252620. eCollection 2021.
8
Emerging concepts in PD-1 checkpoint biology.PD-1 检查点生物学的新观点。
Semin Immunol. 2021 Feb;52:101480. doi: 10.1016/j.smim.2021.101480. Epub 2021 May 15.
9
Identifying key questions in the ecology and evolution of cancer.确定癌症生态与进化中的关键问题。
Evol Appl. 2021 Feb 8;14(4):877-892. doi: 10.1111/eva.13190. eCollection 2021 Apr.
10
Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single-center experience.识别免疫检查点抑制剂治疗中的脑病：单中心经验。
Cancer Med. 2021 May;10(9):2978-2986. doi: 10.1002/cam4.3818. Epub 2021 Mar 3.
本文引用的文献
1
PD-1 regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.PD-1 阻断扩增的 PD-1 调节性 T 细胞促进癌症的过度进展。
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008. doi: 10.1073/pnas.1822001116. Epub 2019 Apr 26.
2
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.早期免疫治疗试验中的超进展性疾病：临床预测因素及与免疫相关毒性的关联。
Cancer. 2019 Apr 15;125(8):1341-1349. doi: 10.1002/cncr.31999. Epub 2019 Feb 15.
3
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.纳武利尤单抗作为抗 PD-1 治疗晚期胃癌患者中 hyperprogressive disease 的预测因素。
Gastric Cancer. 2019 Jul;22(4):793-802. doi: 10.1007/s10120-018-00922-8. Epub 2019 Jan 9.
4
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.抗体 Fc/FcR 相互作用在巨噬细胞中作为 PD-1/PD-L1 阻断后非小细胞肺癌发生超进展性疾病的机制。
Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390. Epub 2018 Sep 11.
5
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.抗 PD-1/PD-L1 抑制剂或单药化疗治疗的晚期非小细胞肺癌患者的超进展性疾病。
JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.
6
Blockade of Tumor-Expressed PD-1 promotes lung cancer growth.肿瘤表达的PD-1的阻断促进肺癌生长。
Oncoimmunology. 2018 Jan 29;7(4):e1408747. doi: 10.1080/2162402X.2017.1408747. eCollection 2018.
7
Genomics of Immunotherapy-Associated Hyperprogressors-Letter.免疫治疗相关超进展者的基因组学——信函
Clin Cancer Res. 2017 Oct 15;23(20):6374-6375. doi: 10.1158/1078-0432.CCR-17-1480.
8
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.抗 PD-1/PD-L1 治疗复发性和/或转移性头颈部鳞状细胞癌患者中的超进展。
Ann Oncol. 2017 Jul 1;28(7):1605-1611. doi: 10.1093/annonc/mdx178.
9
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.免疫治疗后的超进展者：与加速生长率相关的基因组改变分析。
Clin Cancer Res. 2017 Aug 1;23(15):4242-4250. doi: 10.1158/1078-0432.CCR-16-3133. Epub 2017 Mar 28.
10
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.抗 PD-1/PD-L1 治疗的癌症患者中出现的一种新的疾病进展模式：超进展性疾病
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741. Epub 2016 Nov 8.
Zotero 插件